Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.
美國 FDA 不良事件報告系統中鈉-葡萄糖共轉運蛋白 2 抑制劑與腎癌的關聯。
Eur J Clin Pharmacol 2024-09-16
Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials.
鈉葡萄糖共同轉運蛋白-2抑制劑與癌症結果:隨機對照試驗的系統性回顧和荟萃分析。
Diabetes Res Clin Pract 2023-04-10
Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk.
糖尿病患者使用和不使用鈉葡萄糖共同轉運蛋白2抑製劑與發生癌症風險。
J Diabetes Complications 2023-06-13
Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.
葡萄糖鈉共同運輸蛋白2抑制劑與二肽基胜肽酶4抑制劑在糖尿病患者中新發癌症風險的比較:一項真實世界證據研究。
Diabetes Metab Res Rev 2024-02-26
Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
糖尿病患者使用鈉葡萄糖協同轉運蛋白-2抑制劑治療後腎細胞癌風險降低。
Cancer Sci 2024-04-04
Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis.
SGLT2 抑制劑治療對患有第二型糖尿病和癌症患者的心血管結果:系統性回顧和荟萃分析。
Diabetol Metab Syndr 2024-05-21
Type Disparity in Sodium-Glucose Cotransporter-2 Inhibitors in Incidences of Renal Cell Carcinoma: A Propensity-Score-Matched Cohort Study.
SGLT-2抑制劑在腎細胞癌發生率中的型別差異:一項傾向性配對的世代研究。
Cancers (Basel) 2024-06-19
Deciphering the Causal Relationship between Sodium-glucose Cotransporter 2 Inhibition and Cancer Risks: A Comprehensive Mendelian Randomization Study.
藉由全面的Mendelian Randomization研究解讀鈉葡萄糖共轉運輸蛋白2抑制與癌症風險之因果關係。
J Cancer 2024-06-24
Comparison over Time of Adverse Drug Reactions in Diabetes Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors.
糖尿病患者使用鈉-葡萄糖共轉運蛋白 2 抑制劑的藥物不良反應隨時間的比較。
Kobe J Med Sci 2024-08-07